{"id":"CHEMBL1116","canonicalSmiles":"Cl.O=C(c1ccc(OCCN2CCCCC2)cc1)c1c(-c2ccc(O)cc2)sc2cc(O)ccc12","inchiKey":"BKXVVCILCIUCLG-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":true,"name":"RALOXIFENE HYDROCHLORIDE","yearOfFirstApproval":1997,"maximumClinicalTrialPhase":4,"parentId":"CHEMBL81","hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Evirex","Evista","Optruma","Ostiral","Raloxifene hydrochloride","Razylan"],"synonyms":["Keoxifene hydrochloride","LY-156758","LY156758","NSC-706725","Raloxifene hcl","Raloxifene hydrochloride","Raloxifene teva"],"crossReferences":{"DailyMed":["raloxifene%20hydrochloride"],"PubChem":["144203806","144212686","170465341","26753259","26753260","50106949","50106950","56320710","56324093"],"chEBI":["50740"]},"linkedTargets":{"rows":["ENSG00000140009"],"count":1},"linkedDiseases":{"rows":["MONDO_0005090","MONDO_0007254","EFO_0000673","EFO_0003882","EFO_0005411"],"count":5},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1997 and is indicated for breast cancer and osteoporosis and has 1 investigational indication. This drug has a black box warning from the FDA."}
{"id":"CHEMBL119084","canonicalSmiles":"NS(=O)(=O)c1ccc(C(=O)NCCCCNCS)cc1","inchiKey":"XLYYIFIRODREFK-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL119084","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB04002"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL1200411","canonicalSmiles":"CCCN(CCC)CCc1cccc2c1CC(=O)N2.Cl","inchiKey":"XDXHAEQXIBQUEZ-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":true,"name":"ROPINIROLE HYDROCHLORIDE","yearOfFirstApproval":1997,"maximumClinicalTrialPhase":4,"parentId":"CHEMBL589","hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Adartrel","Aimpart xl","Ipinnia xl","Ralnea xl","Raponer xl","Repinex xl","Requip","Requip xl","Ropilynz xl","Ropinirole hydrochloride","Spiroco xl"],"synonyms":["Ropinirole (as hydrochloride)","Ropinirole hcl","Ropinirole hydrochloride","SK&F 101468-A","SK&F-101468-A"],"crossReferences":{"DailyMed":["ropinirole%20hydrochloride"],"PubChem":["50107005"]},"linkedTargets":{"rows":["ENSG00000149295","ENSG00000069696","ENSG00000151577"],"count":3},"linkedDiseases":{"rows":["MONDO_0005180","EFO_0004270"],"count":2},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1997 and is indicated for parkinson disease and restless legs syndrome. This drug has a black box warning from the FDA."}
{"id":"CHEMBL1200633","canonicalSmiles":"CC[C@H](C)[C@H]1O[C@]2(CC[C@@H]1C)C[C@@H]1C[C@@H](C/C=C(\\C)[C@@H](O[C@H]3C[C@H](OC)[C@@H](O[C@H]4C[C@H](OC)[C@@H](O)[C@H](C)O4)[C@H](C)O3)[C@@H](C)/C=C/C=C3\\CO[C@@H]4[C@H](O)C(C)=C[C@@H](C(=O)O1)[C@]34O)O2.CO[C@H]1C[C@H](O[C@H]2[C@H](C)O[C@@H](O[C@@H]3/C(C)=C/C[C@@H]4C[C@@H](C[C@]5(CC[C@H](C)[C@@H](C(C)C)O5)O4)OC(=O)[C@@H]4C=C(C)[C@@H](O)[C@H]5OC/C(=C\\C=C\\[C@@H]3C)[C@@]45O)C[C@@H]2OC)O[C@@H](C)[C@@H]1O","inchiKey":"SPBDXSGPUHCETR-JFUDTMANSA-N","drugType":"Unknown","blackBoxWarning":false,"name":"IVERMECTIN","yearOfFirstApproval":1996,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Cardomec","Eqvalan","Heartguard","Ivermectin","Ivomec","Mectizan","Sklice","Soolantra","Stromectol"],"synonyms":["22,23-dihydro c-076b1","22,23-dihydroabamectin","22,23-dihydroavermectin b1","22,23-dihydroavermectin b1a","Acarexx","Bimectin","Bovinet","CD-5024","CD5024","Cardomec","Cardotek 30","Cevamec","Dihydroavermectin b1a","Equimec","Eqvalan","Heartgard","Hyvermectin","Ivectin","Ivermectin","Ivermectin b1a","Ivermectin component b1a","Ivertin","Ivomec","Ivosint","Jetamec","L 640471","L-640471","MK 933","MK-933","Mectizan","NSC-755843","Noramectin","Noromectin","Oramec","Pandex","Phoenectin","Uvemec","Vermic","Vetmec","Zimecterin"],"crossReferences":{"DailyMed":["ivermectin"],"DrugCentral":["3972"]},"description":"Unknown drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1996 and has 5 approved and 12 investigational indications."}
{"id":"CHEMBL1200725","canonicalSmiles":"Clc1ccc(C(Cn2ccnc2)OCc2csc3c(Cl)cccc23)c(Cl)c1.O=[N+]([O-])O","inchiKey":"HAAITRDZHUANGT-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"SERTACONAZOLE NITRATE","yearOfFirstApproval":2003,"maximumClinicalTrialPhase":4,"parentId":"CHEMBL1201196","hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Dermofix","Ertaczo"],"synonyms":["Dermofix","Dermovit","FI 7056","FI-7056","Sertaconazole mononitrate","Sertaconazole nitrate","Zalain"],"crossReferences":{"DailyMed":["sertaconazole%20nitrate"],"PubChem":["144204269","56463153"]},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2003 and is indicated for tinea pedis and has 1 investigational indication."}
{"id":"CHEMBL1200787","canonicalSmiles":"CC(COc1ccccc1)N(CCCl)Cc1ccccc1.Cl","inchiKey":"VBCPVIWPDJVHAN-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"PHENOXYBENZAMINE HYDROCHLORIDE","yearOfFirstApproval":1953,"maximumClinicalTrialPhase":4,"parentId":"CHEMBL753","hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Dibenyline","Dibenzyline","Phenoxybenzamine hydrochloride"],"synonyms":["Bensylyte hydrochloride","Dibenzylin","Dibenzyline chloride","Dibenzyline hydrochloride","Dibenzyran","NSC-37448","Phenoxybenzamine chloride","Phenoxybenzamine hcl","Phenoxybenzamine hydrochloride"],"crossReferences":{"DailyMed":["phenoxybenzamine%20hydrochloride"],"PubChem":["144208786","144213295","17389764","26747462","26752311","50105976","855636"],"chEBI":["8078"]},"linkedTargets":{"rows":["ENSG00000184160","ENSG00000274286","ENSG00000171873","ENSG00000170214","ENSG00000120907","ENSG00000150594"],"count":6},"linkedDiseases":{"rows":["EFO_0000239"],"count":1},"description":"Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1953 and is indicated for adrenal gland pheochromocytoma."}
{"id":"CHEMBL1201037","canonicalSmiles":"Cl.NCCCC(N)(C(=O)O)C(F)F.O","inchiKey":"FJPAMFNRCFEGSD-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"EFLORNITHINE HYDROCHLORIDE","yearOfFirstApproval":1990,"maximumClinicalTrialPhase":4,"parentId":"CHEMBL830","hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Ornidyl","Vaniqa"],"synonyms":["Dfmo hcl","Difluromethylornithine","Eflornithine hcl","Eflornithine hydrochloride","Eflornithine hydrochloride monohydrate","MDL 71,782 A","MDL-71782-A","MDL-71782A","NSC-270295","NSC-337250","RMI-71782-A"],"crossReferences":{"DailyMed":["eflornithine%20hydrochloride"]},"linkedTargets":{"rows":["ENSG00000115758"],"count":1},"linkedDiseases":{"rows":["Orphanet_733","EFO_0000621"],"count":2},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1990 and has 3 investigational indications."}
{"id":"CHEMBL1201168","canonicalSmiles":"Cc1cc(C(=O)NNCc2ccccc2)no1","inchiKey":"XKFPYPQQHFEXRZ-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":true,"name":"ISOCARBOXAZID","yearOfFirstApproval":1959,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Marplan"],"synonyms":["Enerzer","Isocarboxazid","NSC-169893","RO 5-0831","RO-5-0831"],"crossReferences":{"DailyMed":["isocarboxazid"],"PubChem":["11112152","144203887","56463226"],"Wikipedia":["Isocarboxazid"],"drugbank":["DB01247"]},"linkedTargets":{"rows":["ENSG00000189221","ENSG00000069535"],"count":2},"linkedDiseases":{"rows":["MONDO_0002009","MONDO_0004975","EFO_0003761"],"count":3},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1959 and is indicated for unipolar depression and major depressive disorder and has 1 investigational indication. This drug has a black box warning from the FDA."}
{"id":"CHEMBL1201195","canonicalSmiles":"CO[C@@]1(NC(=O)CSCC#N)C(=O)N2C(C(=O)O)=C(CSc3nnnn3C)CS[C@@H]21","inchiKey":"SNBUBQHDYVFSQF-HIFRSBDPSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CEFMETAZOLE","yearOfFirstApproval":1989,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":[],"synonyms":["Cefmetazole","U-72791"],"crossReferences":{"PubChem":["90341375"],"Wikipedia":["Cefmetazole"],"drugbank":["DB00274"],"chEBI":["3489"]},"childChemblIds":["CHEMBL1201118"],"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1989 and is indicated for bacterial disease and has 2 investigational indications."}
{"id":"CHEMBL1201212","canonicalSmiles":"COc1ccc(OC)c(C(O)CNC(=O)CN)c1","inchiKey":"PTKSEFOSCHHMPD-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":true,"name":"MIDODRINE","yearOfFirstApproval":1996,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":[],"synonyms":["Midodrine","ST 1085","ST-1085"],"crossReferences":{"DailyMed":["midodrine%20hydrochloride"],"drugbank":["DB00211"],"chEBI":["6933"]},"childChemblIds":["CHEMBL1200461"],"linkedTargets":{"rows":["ENSG00000171873","ENSG00000170214","ENSG00000120907"],"count":3},"linkedDiseases":{"rows":["HP_0100806","HP_0002140","EFO_1001346","EFO_0006834","EFO_0000712","EFO_0005252","EFO_1001919","EFO_1001488","EFO_0000319","EFO_0005251","HP_0001541"],"count":11},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1996 and is indicated for cardiovascular disease and has 10 investigational indications. This drug has a black box warning from the FDA."}
{"id":"CHEMBL1201630","drugType":"Protein","blackBoxWarning":false,"name":"INSULIN PURIFIED PORK","yearOfFirstApproval":1979,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Iletin ii","Regular iletin ii (pork)","Regular purified pork insulin","Velosulin"],"synonyms":["Insulin (pork)","Insulin purified pork"],"linkedTargets":{"rows":["ENSG00000171105"],"count":1},"linkedDiseases":{"rows":["EFO_0000400"],"count":1},"description":"Protein drug with a maximum clinical trial phase of IV that was first approved in 1979 and is indicated for diabetes mellitus."}
{"id":"CHEMBL1201640","drugType":"Protein","blackBoxWarning":false,"name":"INSULIN ZINC SUSP EXTENDED BEEF","yearOfFirstApproval":1982,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Ultralente insulin"],"synonyms":["Insulin zinc susp extended beef"],"description":"Protein drug with a maximum clinical trial phase of IV that was first approved in 1982."}
{"id":"CHEMBL1230806","canonicalSmiles":"N[C@H]1C=C(CO)[C@@H](O)[C@H](O)[C@H]1O","inchiKey":"XPHOBMULWMGEBA-VZFHVOOUSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"VALIENAMINE","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Valienamine"],"crossReferences":{"Wikipedia":["Valienamine"],"drugbank":["DB02120"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL1231013","canonicalSmiles":"Cc1cccc(C[C@H](N)C(=O)O)c1","inchiKey":"JZRBSTONIYRNRI-VIFPVBQESA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL1231013","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB02685"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL1231377","canonicalSmiles":"Cc1ccc2c(c1)N=C1N(c3ccccc3)CC[C@@]1(O)C2=O","inchiKey":"KAJFGRLMKVNMLH-GOSISDBHSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL1231377","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB07469"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL1231689","canonicalSmiles":"COc1cc(C)c(S(=O)(=O)N[C@@H](CC(=O)O)C(=O)N[C@H](Cc2ccc(C(=N)N)cc2)C(=O)N2CCCCC2)c(C)c1C","inchiKey":"ZOXOKTJHZSUHRJ-XZOQPEGZSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL1231689","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB03081"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL1256958","canonicalSmiles":"CNC[C@H](O)c1ccc(O)c(O)c1.O=C(O)C(O)C(O)C(=O)O","inchiKey":"YLXIPWWIOISBDD-FVGYRXGTSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"EPINEPHRINE BITARTRATE","yearOfFirstApproval":1965,"maximumClinicalTrialPhase":4,"parentId":"CHEMBL679","hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Bronitin","Bronitin mist","Medihaler-epi"],"synonyms":["(-)-Epinephrine Bitartrate","Adrenalin tartrate","Adrenaline (as tartrate)","Adrenaline acid tartrate","Adrenaline bitartate","Adrenaline bitartrate","Epinephrine bitartrate","Epinephrine d-bitartrate","Epinephrine hydrogen tartrate","Epinephrine tartrate","Epinephrini hydrogenotartras","L-epinephrine hydrogen tartrate","NSC-756755"],"crossReferences":{"DailyMed":["epinephrine%20bitartrate"],"PubChem":["11532860","50106283"]},"linkedTargets":{"rows":["ENSG00000184160","ENSG00000274286","ENSG00000169252","ENSG00000171873","ENSG00000170214","ENSG00000120907","ENSG00000043591","ENSG00000188778","ENSG00000150594"],"count":9},"linkedDiseases":{"rows":["EFO_0003843"],"count":1},"description":"Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1965 and is indicated for pain."}
{"id":"CHEMBL131","canonicalSmiles":"C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO","inchiKey":"OIGNJSKKLXVSLS-VWUMJDOOSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"PREDNISOLONE","yearOfFirstApproval":1955,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Cortalone","Dekotil","Delta-cortef","Deltacortril","Deltalone","Dilacort","Fernisolone-p","Hydeltra","Meti-derm","Meticortelone","Pevanti","Precortisyl","Precortisyl fte","Prednisolone","Prelone","Scheriproct","Servisone","Sterane"],"synonyms":["Desowen","Hydeltra-Tba","Meticortelone","NSC-9120","NSC-9900","Neo-Delta-Cortef","Poly-Pred","Pred-G","Prednisolone","Servisone","Tridesilon","Verdeso"],"crossReferences":{"DailyMed":["prednisolone"],"PubChem":["144204880","144208871","144213304","170464732","50085972"],"Wikipedia":["Prednisolone"],"drugbank":["DB00860"],"chEBI":["8378"]},"linkedTargets":{"rows":["ENSG00000113580"],"count":1},"linkedDiseases":{"rows":["EFO_0004190","EFO_0007486","EFO_0000756","EFO_1001345","EFO_0005952","HP_0004798","Orphanet_141127","HP_0011950","EFO_1001077","EFO_0000096","EFO_0002690","EFO_0003884","EFO_0004616","EFO_0000676","EFO_0008517","HP_0003072","EFO_0009449","HP_0000964","EFO_0007537","EFO_1001968","HP_0001742","EFO_0000384","EFO_0000660","MONDO_0008315","EFO_0001663","EFO_1001231","MONDO_0020290","MONDO_0044889","EFO_1000391","EFO_0003032","EFO_1000049","EFO_0000574","MONDO_0004979","EFO_0001378","EFO_0000341","EFO_0001054","EFO_0000516","EFO_1001887","EFO_0009491","EFO_0003086","EFO_1001896","EFO_0007405","EFO_1001205","EFO_0001365","EFO_1000997","MONDO_0007254","MONDO_0005271","EFO_0000255","HP_0010450","MONDO_0016236","EFO_1000684","HP_0004448","MONDO_0003541","EFO_1000694","Orphanet_3451","EFO_0004289","EFO_0000196","EFO_0007208","EFO_0004826","EFO_0000183","MONDO_0002083","EFO_0005752","Orphanet_797","EFO_0000280","EFO_0000403","EFO_0003898","MONDO_0000870","EFO_0000222","EFO_0003843","HP_0002315","EFO_1000954","EFO_0001060","EFO_0007257","EFO_0005297","EFO_0000764","EFO_1001194","EFO_1001373","MONDO_0018906","EFO_0007141","EFO_0007167","MONDO_0024880","MONDO_0005178","MONDO_0005148","EFO_0003956","EFO_0003872","EFO_0000729","Orphanet_309015","EFO_1001069","MONDO_0000873","EFO_1001139","EFO_0004274","EFO_0005558","EFO_1001110","EFO_0008997","EFO_0000565","EFO_0007160","EFO_0009456","EFO_0007520","EFO_1000680","MONDO_0019088","EFO_0000182","EFO_0004255","MONDO_0015540","EFO_0009552","EFO_1000749","EFO_0005854","EFO_0000759","EFO_0005761","EFO_0000220","EFO_1000039","EFO_0004236","EFO_0004194","EFO_1002029","HP_0001873","EFO_1000784","EFO_1001119","Orphanet_418","EFO_0004239","Orphanet_98896","HP_0100806","EFO_1001209","MP_0001845","MONDO_0100096","MONDO_0001208","Orphanet_90794","EFO_0000398","EFO_1001051","HP_0012424","EFO_0007415","EFO_1001222","Orphanet_30391","MONDO_0005090","MONDO_0003005","EFO_0005319","EFO_1000764","EFO_0000768","EFO_1001020","EFO_1001435","HP_0001094","EFO_0003778","MONDO_0001280","EFO_0000274","HP_0001915","EFO_1001264","EFO_0000209","EFO_1001888","MONDO_0002462","EFO_0009715","EFO_0004246","HP_0004398","HP_0000083","EFO_0008518","EFO_0000474","EFO_0004254","MONDO_0005129","Orphanet_141","EFO_0000673","EFO_0003938","MONDO_0020743","EFO_0007427","EFO_1000726","EFO_0000717","EFO_1000635","EFO_0009609","EFO_0000685","MONDO_0015128","HP_0002140","EFO_0000545","EFO_0007140","EFO_1001321","EFO_1000941","EFO_0004237","EFO_0002609","EFO_0000311","MONDO_0001705","EFO_0000211","EFO_0003106","EFO_0007227","MONDO_0005301","EFO_0007403","EFO_0007387","EFO_1001467","EFO_0003918"],"count":183},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1955 and has 58 approved and 89 investigational indications."}
{"id":"CHEMBL1431","canonicalSmiles":"CN(C)C(=N)NC(=N)N","inchiKey":"XZWYZXLIPXDOLR-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":true,"name":"METFORMIN","yearOfFirstApproval":1995,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":[],"synonyms":["LA-6023","Metformin","Metformin extended release"],"crossReferences":{"DailyMed":["metformin%20hydrochloride"],"PubChem":["11112469","137275802","144212687","174006543"],"TG-GATEs":["53"],"Wikipedia":["Metformin"],"drugbank":["DB00331"],"chEBI":["6801"]},"childChemblIds":["CHEMBL3094198","CHEMBL1703"],"linkedTargets":{"rows":["ENSG00000178127","ENSG00000186010","ENSG00000137806","ENSG00000267855","ENSG00000119421","ENSG00000166136","ENSG00000198695","ENSG00000198840","ENSG00000158864","ENSG00000184983","ENSG00000168653","ENSG00000184752","ENSG00000099795","ENSG00000164258","ENSG00000065518","ENSG00000147684","ENSG00000131495","ENSG00000170906","ENSG00000109390","ENSG00000151366","ENSG00000004779","ENSG00000165264","ENSG00000198886","ENSG00000115159","ENSG00000145494","ENSG00000125356","ENSG00000123545","ENSG00000090266","ENSG00000128609","ENSG00000198763","ENSG00000119013","ENSG00000174886","ENSG00000140990","ENSG00000213619","ENSG00000189043","ENSG00000178057","ENSG00000160194","ENSG00000164182","ENSG00000136521","ENSG00000167792","ENSG00000115286","ENSG00000139180","ENSG00000023228","ENSG00000185633","ENSG00000183648","ENSG00000130414","ENSG00000110717","ENSG00000212907","ENSG00000147123","ENSG00000198786","ENSG00000198888"],"count":51},"linkedDiseases":{"rows":["EFO_1000419","EFO_0001361","EFO_0000365","EFO_1000710","EFO_0000275","EFO_0008569","EFO_0000756","EFO_1001390","EFO_0000308","MONDO_0044704","EFO_1001951","EFO_0003914","HP_0100543","EFO_1001492","EFO_0003931","EFO_1001459","EFO_0002690","MONDO_0002974","MONDO_0008903","EFO_0003884","EFO_0000676","Orphanet_827","EFO_1001348","HP_0002910","EFO_0000400","MONDO_0001941","HP_0000842","EFO_0005762","EFO_0002618","EFO_0005922","EFO_1001512","EFO_1000782","EFO_1001496","EFO_0000660","MONDO_0008315","EFO_0001663","MONDO_0002691","GO_0007568","Orphanet_399","EFO_0001378","EFO_0000341","EFO_0001054","EFO_0004364","HP_0001249","EFO_0009637","EFO_0004214","Orphanet_84","EFO_1001465","MONDO_0007254","Orphanet_98473","EFO_0001071","EFO_0003847","MONDO_0002158","EFO_0000289","MONDO_0002050","EFO_0003968","EFO_0003100","EFO_0000196","EFO_0000707","EFO_0002546","HP_0001541","HP_0012115","EFO_0000616","EFO_0000280","EFO_0000694","EFO_0006859","EFO_0001645","EFO_0000403","EFO_0000319","EFO_0001073","EFO_0000537","EFO_1000954","MONDO_0021350","EFO_0000195","EFO_0004220","EFO_1001892","EFO_0010269","EFO_1001121","EFO_0000649","EFO_0000764","EFO_0002614","MONDO_0011962","EFO_0000199","EFO_0002517","EFO_0000702","EFO_1001207","MONDO_0018906","MONDO_0005148","EFO_0005411","EFO_0000519","MONDO_0005178","EFO_0004265","Orphanet_524","EFO_0000729","HP_0001397","EFO_0001075","EFO_0003095","MONDO_0002009","EFO_0000571","HP_0001268","EFO_1000657","MONDO_0004222","EFO_1000235","EFO_0000228","EFO_0004593","Orphanet_733","EFO_0000182","HP_0003419","EFO_0003940","EFO_1000045","EFO_0001416","EFO_0005761","Orphanet_100","HP_0003124","MONDO_0004658","EFO_0000466","Orphanet_325546","EFO_0002687","EFO_0000220","MONDO_0008170","Orphanet_3389","EFO_0009516","MONDO_0000396","Orphanet_309005","Orphanet_98896","MP_0001845","MONDO_0100096","EFO_0005537","EFO_0000233","EFO_0000432","MONDO_0005090","EFO_0004566","Orphanet_282","Orphanet_232","EFO_1001901","MONDO_0015686","EFO_1001249","EFO_1001461","MONDO_0021063","MONDO_0002087","EFO_0003876","EFO_0000305","EFO_1000357","MONDO_0001187","EFO_0002950","EFO_1000783","EFO_1001480","EFO_1000044","MONDO_0041161","EFO_1000043","MONDO_0005277","EFO_0003144","EFO_0000673","EFO_1000660","EFO_0003047","EFO_0002617","EFO_0000685","EFO_0000545","EFO_0003963","EFO_0000677","HP_0011015","EFO_0000313","EFO_0003770","Orphanet_110","EFO_0003060","EFO_0000311","Orphanet_908","EFO_0000589","EFO_0003863","EFO_0001068","MONDO_0004782","MONDO_0005301","EFO_0000095","MONDO_0005147","EFO_0001421","EFO_0004142","EFO_0003050","EFO_0003918","EFO_0003833","EFO_0000181"],"count":180},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1995 and is indicated for diabetes mellitus and type 2 diabetes mellitus and has 154 investigational indications. This drug has a black box warning from the FDA."}
{"id":"CHEMBL1434513","canonicalSmiles":"NC[C@H](O)c1ccc(O)c(O)c1.O.O=C(O)C(O)C(O)C(=O)O","inchiKey":"LNBCGLZYLJMGKP-JZGIKJSDSA-N","drugType":"Small molecule","blackBoxWarning":true,"name":"NOREPINEPHRINE BITARTRATE","yearOfFirstApproval":1950,"maximumClinicalTrialPhase":4,"parentId":"CHEMBL1437","hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Adrenor","Aktamin","Levarterenol Bitartrate","Levophed","Noradrenaline","Norepinephrine bitartrate","Norepinephrine bitartrate in 5% dextrose"],"synonyms":["Aktamin","Arterenol, tartrate, monohydrate","Binodrenal","Levarterenol bitartrate","NSC-169106","Noradrenaline","Noradrenaline (as tartrate)","Noradrenaline bitartrate","Noradrenaline tartrate","Norepinephrine","Norepinephrine bitartrate","Norepinephrine bitartrate monohydrate","Norepinephrine d-bitartrate","Norepinephrine hydrochloride"],"crossReferences":{"DailyMed":["norepinephrine%20bitartrate"],"PubChem":["56463315"]},"linkedTargets":{"rows":["ENSG00000274286","ENSG00000184160","ENSG00000169252","ENSG00000171873","ENSG00000170214","ENSG00000120907","ENSG00000043591","ENSG00000188778","ENSG00000150594"],"count":9},"linkedDiseases":{"rows":["EFO_0004610","HP_0100806","HP_0000083","HP_0002140","EFO_0006834","EFO_0000319","EFO_0002497","EFO_0007450","EFO_0005251"],"count":9},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1950 and has 3 approved and 4 investigational indications. This drug has a black box warning from the FDA."}
{"id":"CHEMBL1481873","canonicalSmiles":"COP(=S)(OC)SCN1C(=O)c2ccccc2C1=O","inchiKey":"LMNZTLDVJIUSHT-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"PHOSMET","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Phosmet"],"crossReferences":{"PubChem":["144204544","144209514","144210413","170466810","50085458","7974290","84986995"],"drugbank":["DB11448"],"chEBI":["38786"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL1630578","canonicalSmiles":"C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)C3=CC[C@]2(C)[C@H]1C(=O)CN1CCN(c2cc(N3CCCC3)nc(N3CCCC3)n2)CC1","inchiKey":"RBKASMJPSJDQKY-RBFSKHHSSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"TIRILAZAD","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Tirilazad","U 74006","U-74006"],"crossReferences":{"Wikipedia":["Tirilazad"],"drugbank":["DB13050"]},"childChemblIds":["CHEMBL3989513"],"description":"Small molecule drug with a maximum clinical trial phase of III and has 1 investigational indication."}
{"id":"CHEMBL16498","canonicalSmiles":"C=C1C[C@H]2C=Nc3cc(OCCCOc4cc5c(cc4OC)C(=O)N4CC(=C)C[C@H]4C=N5)c(OC)cc3C(=O)N2C1","inchiKey":"RWZVMMQNDHPRQD-SFTDATJTSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"SJG-136","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["BN-2629","NSC-694501","SG-2000","SJG-136","SP-2001","Sjg 136","Sjg-136","UP-2001"],"crossReferences":{"PubChem":["524417"],"drugbank":["DB11965"]},"description":"Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."}
{"id":"CHEMBL1703","canonicalSmiles":"CN(C)C(=N)N=C(N)N.Cl","inchiKey":"OETHQSJEHLVLGH-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":true,"name":"METFORMIN HYDROCHLORIDE","yearOfFirstApproval":1995,"maximumClinicalTrialPhase":4,"parentId":"CHEMBL1431","hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Bolamyn sr","Diagemet xl","Fortamet","Glucamet 500","Glucamet 850","Glucient sr","Glucophage","Glucophage sr","Glucophage xr","Glumetza","Glyformin","Janumet","Ledermetin","Metabet sr","Metformin hydrochloride","Metsol","Milform","Orabet","Riomet","Riomet er","Sukkarto sr"],"synonyms":["Apophage","Benofomin","Diabefagos","Diabex","EX-404","EX404","Glucaminol","LA-6023","Metformin hcl","Metformin hydrochloride","NSC-91485","Neodipa","Siamformet","Walaphage"],"crossReferences":{"DailyMed":["metformin%20hydrochloride"],"PubChem":["11532867","144204049","170464804","26749076","85273756"],"chEBI":["6802"]},"linkedTargets":{"rows":["ENSG00000178127","ENSG00000186010","ENSG00000137806","ENSG00000267855","ENSG00000119421","ENSG00000166136","ENSG00000198695","ENSG00000198840","ENSG00000184983","ENSG00000158864","ENSG00000168653","ENSG00000184752","ENSG00000099795","ENSG00000164258","ENSG00000065518","ENSG00000151366","ENSG00000147684","ENSG00000109390","ENSG00000170906","ENSG00000131495","ENSG00000004779","ENSG00000165264","ENSG00000198886","ENSG00000115159","ENSG00000145494","ENSG00000125356","ENSG00000128609","ENSG00000123545","ENSG00000090266","ENSG00000119013","ENSG00000198763","ENSG00000174886","ENSG00000140990","ENSG00000213619","ENSG00000189043","ENSG00000178057","ENSG00000160194","ENSG00000164182","ENSG00000136521","ENSG00000167792","ENSG00000115286","ENSG00000139180","ENSG00000023228","ENSG00000185633","ENSG00000183648","ENSG00000130414","ENSG00000110717","ENSG00000147123","ENSG00000212907","ENSG00000198786","ENSG00000198888"],"count":51},"linkedDiseases":{"rows":["Orphanet_84","EFO_1000419","HP_0001397","EFO_0000571","EFO_1001465","MONDO_0007254","MONDO_0004222","EFO_0001071","MONDO_0021063","MONDO_0002087","EFO_1000235","EFO_1000357","EFO_1000783","MONDO_0002158","EFO_1000043","EFO_1001459","EFO_0004593","EFO_1000044","EFO_0003144","EFO_0003884","EFO_0000673","Orphanet_827","EFO_0000400","HP_0000842","HP_0001541","EFO_0002618","EFO_0006859","EFO_0000466","EFO_1001512","EFO_0001073","EFO_0000660","MONDO_0008315","EFO_0001663","EFO_0003060","EFO_0000195","MP_0001845","EFO_1001121","EFO_0002517","EFO_0000199","EFO_0000432","EFO_0001378","MONDO_0005148","EFO_0009637"],"count":43},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1995 and is indicated for diabetes mellitus and type 2 diabetes mellitus and has 33 investigational indications. This drug has a black box warning from the FDA."}
{"id":"CHEMBL1742995","drugType":"Antibody","blackBoxWarning":false,"name":"BRIAKINUMAB","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":["Ozespa"],"synonyms":["A-796874.0","ABT-874","BSF 415977","BSF-415977","Briakinumab","J-695","J-695 BSF-415977 LU-415977 WAY-165772 A-796874.0","J695","LU 415977","LU-415977","WAY-165772"],"linkedTargets":{"rows":["ENSG00000113302"],"count":1},"linkedDiseases":{"rows":["MONDO_0005301","EFO_0000676","EFO_0000540","EFO_0000384"],"count":4},"description":"Antibody drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications."}
{"id":"CHEMBL1794734","canonicalSmiles":"C[C@@](O)(CCO)CC(=O)O","inchiKey":"KJTLQQUUPVSXIM-ZCFIWIBFSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"MEVALONIC ACID","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Mevalonic acid"],"crossReferences":{"drugbank":["DB03518"],"chEBI":["17710"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL2062262","canonicalSmiles":"C[C@H](N)[C@H](O)c1cccc(O)c1.O=C(O)C(O)C(O)C(=O)O","inchiKey":"VENXSELNXQXCNT-YDYUUSCQSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"METARAMINOL BITARTRATE","yearOfFirstApproval":1954,"maximumClinicalTrialPhase":4,"parentId":"CHEMBL1201319","hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Aramine","Metaraminol bitartrate"],"synonyms":["Metaradrine bitartrate","Metaraminol bitartrate","Metaraminol hydrochloride","Metaraminol hydrochloride, (-)-","Metaraminol tartrate","NSC-758425"],"description":"Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1954."}
{"id":"CHEMBL20835","canonicalSmiles":"CC(=O)OC1CN2CCC1CC2","inchiKey":"WRJPSSPFHGNBMG-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"ACECLIDINE","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":["Glaucostat"],"synonyms":["3-quinuclidinol acetate (ester)","3-quinuclidinol dl-form acetate (ester)","Aceclidine","Aceclidine hcl","Aceclidine hydrochloride","NSC-657843","NSC-758239"],"crossReferences":{"PubChem":["26751840","507906"],"Wikipedia":["Aceclidine"],"drugbank":["DB13262"]},"childChemblIds":["CHEMBL4303558"],"description":"Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."}
{"id":"CHEMBL2104054","canonicalSmiles":"CC(=O)c1ccc2c(c1)N(CC(C)N(C)C)c1ccccc1S2","inchiKey":"XLOQNFNTQIRSOX-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"ACEPROMETAZINE","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Aceprometazine","CB 1664","CB-1664"],"crossReferences":{"drugbank":["DB01615"],"chEBI":["53770"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL2105681","canonicalSmiles":"CCCCCCCCCCCCCCCC(=O)Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2C#N)c(=O)n1","inchiKey":"LBGFKUUHOPIEMA-PEARBKPGSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"SAPACITABINE","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["CS-682","CYC-682","CYC682","Sapacitabine"],"crossReferences":{"drugbank":["DB06365"]},"description":"Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 6 investigational indications."}
{"id":"CHEMBL2105721","canonicalSmiles":"CC(C)[C@@]1(C(=O)N[C@H]2CC(=O)O[C@]2(O)CF)CC(c2nccc3ccccc23)=NO1","inchiKey":"VYFGDLGHHBUDTQ-ZLGUVYLKSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"NIVOCASAN","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["GS-9450","LB-84451","LB84451","Nivocasan"],"crossReferences":{"drugbank":["DB12720"]},"linkedTargets":{"rows":["ENSG00000064012","ENSG00000132906","ENSG00000137752"],"count":3},"linkedDiseases":{"rows":["EFO_1001249","EFO_0003047"],"count":2},"description":"Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."}
{"id":"CHEMBL2105738","canonicalSmiles":"C[C@]12CC[C@H]3[C@@H](CC=C4C[C@@H](O)CC[C@@]43C)[C@@H]1CC=C2n1cnc2ccccc21","inchiKey":"PAFKTGFSEFKSQG-PAASFTFBSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"GALETERONE","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Galeterone","TOK 001","TOK-001","VN 124","VN-124","VN/124","VN/124-1"],"crossReferences":{"drugbank":["DB12415"]},"linkedTargets":{"rows":["ENSG00000148795","ENSG00000169083"],"count":2},"linkedDiseases":{"rows":["EFO_0002618","MONDO_0008315"],"count":2},"description":"Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications."}
{"id":"CHEMBL2106627","canonicalSmiles":"CC(=O)Oc1ccc2c3c1O[C@H]1[C@@H](OC(C)=O)C=C[C@H]4[C@@H](C2)N(C)CC[C@]314.Cl","inchiKey":"FZJYQGFGNHGSFX-PVQKIFDLSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"DIACETYLMORPHINE HYDROCHLORIDE","maximumClinicalTrialPhase":4,"parentId":"CHEMBL459324","hasBeenWithdrawn":false,"isApproved":true,"tradeNames":[],"synonyms":["Diacetylmorphine hcl","Diacetylmorphine hydrochloride","Diacetylmorphine hydrochloride ci","Diamorphine","Diamorphine hydrochloride","Heroin hydrochloride","NSC-302357"],"crossReferences":{"PubChem":["144206407"]},"description":"Small molecule drug with a maximum clinical trial phase of IV and is indicated for drug dependence."}
{"id":"CHEMBL2108129","drugType":"Enzyme","blackBoxWarning":false,"name":"SARUPLASE","maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":[],"synonyms":["Saruplase","Scupa"],"description":"Enzyme drug with a maximum clinical trial phase of IV and is indicated for recurrent thrombophlebitis."}
{"id":"CHEMBL2108170","drugType":"Protein","blackBoxWarning":false,"name":"AVISCUMINE","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Aviscumine","CY-503","Cy-503","Mistletoe lectins aviscumine"],"description":"Protein drug with a maximum clinical trial phase of II and has 1 investigational indication."}
{"id":"CHEMBL2108264","drugType":"Unknown","blackBoxWarning":false,"name":"CARRAGEENAN","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":["Marine colloids"],"synonyms":["Aec carrageenan gel","Aec carrageenan powder","Calcium carrageenan","Carrageenan","Carrageenin","E-407","Eucheuman (from eucheuma spp.)","Genugel carrageenan","Genuvisco carrageenan","Hypnean (from hypnea spp.)","INS NO.407","INS-407","Iridophycan (from iridaea spp.)","Potassium carrageenan","Sea spen","Seaspen pf","Sodium carrageenan"],"description":"Unknown drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."}
{"id":"CHEMBL2108316","drugType":"Oligonucleotide","blackBoxWarning":false,"name":"EDIFOLIGIDE","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Edifoligide"],"description":"Oligonucleotide drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL2108348","drugType":"Protein","blackBoxWarning":false,"name":"NONACOG BETA PEGOL","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Nonacog beta pegol","Rebinyn","Refixia"],"description":"Protein drug with a maximum clinical trial phase of III and has 1 investigational indication."}
{"id":"CHEMBL2108357","drugType":"Antibody","blackBoxWarning":false,"name":"EPRATUZUMAB 90Y","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":["Lymphocide"],"synonyms":["AMG-412","Epratuzumab 90y","HLL2"],"linkedTargets":{"rows":["ENSG00000012124"],"count":1},"linkedDiseases":{"rows":["EFO_1001938"],"count":1},"description":"Antibody drug with a maximum clinical trial phase of III and has 1 investigational indication."}
{"id":"CHEMBL2109445","drugType":"Antibody","blackBoxWarning":false,"name":"AD-439","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["AD-439"],"description":"Antibody drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL2110556","drugType":"Protein","blackBoxWarning":false,"name":"INDIUM PENTETREOTIDE","yearOfFirstApproval":1994,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":[],"synonyms":[],"crossReferences":{"DailyMed":["indium%20in-111%20pentetreotide%20kit"]},"childChemblIds":["CHEMBL1200642"],"description":"Protein drug with a maximum clinical trial phase of IV that was first approved in 1994."}
{"id":"CHEMBL2110734","canonicalSmiles":"COCC[n+]1c2c(n(Cc3cnccn3)c1C)C(=O)c1ccccc1C2=O","inchiKey":"OTSOOHRUMBRSHZ-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"SEPANTRONIUM","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Sepantronium cation","Sepantronium ion"],"childChemblIds":["CHEMBL2105734"],"description":"Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 8 investigational indications."}
{"id":"CHEMBL2146126","canonicalSmiles":"[LiH]","inchiKey":"SIAPCJWMELPYOE-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"LITHIUM","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Lithium"],"crossReferences":{"chEBI":["30146"]},"description":"Small molecule drug with a maximum clinical trial phase of III and has 1 investigational indication."}
{"id":"CHEMBL2147777","canonicalSmiles":"Cc1cc(N2CCN([C@@H]3CN[C@H](C(=O)N4CCSC4)C3)CC2)n(-c2ccccc2)n1","inchiKey":"WGRQANOPCQRCME-PMACEKPBSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"TENELIGLIPTIN","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["MP-513","Teneligliptin"],"crossReferences":{"drugbank":["DB11950"]},"childChemblIds":["CHEMBL2147708"],"linkedTargets":{"rows":["ENSG00000197635"],"count":1},"linkedDiseases":{"rows":["MONDO_0005148","EFO_0000400"],"count":2},"description":"Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications."}
{"id":"CHEMBL215226","canonicalSmiles":"CN[C@@H]1[C@@H](O)[C@@H](O[C@@H]2[C@@H](O)[C@H](O[C@H]3O[C@H]([C@@H](C)O)[C@@H](O)[C@H](O)[C@H]3N)[C@@H](N)C[C@H]2N)OC[C@]1(C)O","inchiKey":"BRZYSWJRSDMWLG-DJWUNRQOSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"GENETICIN","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["G418"],"crossReferences":{"Wikipedia":["G418"],"drugbank":["DB04263"]},"childChemblIds":["CHEMBL2206186"],"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL221692","canonicalSmiles":"Fc1ccc(-c2cncc(CN3CCN(c4cccc5c4OCCO5)CC3)c2)cc1","inchiKey":"IUVSEUFHPNITEQ-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"ADOPRAZINE","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Adoprazine","SLV-313"],"childChemblIds":["CHEMBL4751170"],"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL222501","canonicalSmiles":"C=CCn1nc(-c2ccc(O)cc2O)c2cccc(C(F)(F)F)c21","inchiKey":"ZDUDMCQPFKPISO-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"WAY-169916","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["WAY-169916"],"crossReferences":{"drugbank":["DB08047"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL2386346","canonicalSmiles":"CCOc1cc(C(C)(C)C)ccc1C1=N[C@@](C)(c2ccc(Cl)cc2)[C@@](C)(c2ccc(Cl)cc2)N1C(=O)N1CCN(CCCS(C)(=O)=O)CC1","inchiKey":"QBGKPEROWUKSBK-QPPIDDCLSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"RO-5045337","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Mdm2 antagonist ro5045337","R 7112","RG-7112","RG7112","RO-5045337","RO5045337","Ro-5045337"],"crossReferences":{"drugbank":["DB14793"]},"description":"Small molecule drug with a maximum clinical trial phase of I (across all indications) and has 3 investigational indications."}
{"id":"CHEMBL2424780","canonicalSmiles":"CCCCOc1nc(N)c2c(n1)N(Cc1cccc(CN3CCCC3)c1)CC(=O)N2","inchiKey":"VFOKSTCIRGDTBR-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"VESATOLIMOD","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["GS-9620","Vesatolimod"],"crossReferences":{"drugbank":["DB12687"]},"linkedTargets":{"rows":["ENSG00000196664"],"count":1},"linkedDiseases":{"rows":["EFO_0000765","EFO_0000180","EFO_0004197","EFO_0003047","EFO_0004239"],"count":5},"description":"Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications."}
{"id":"CHEMBL255476","canonicalSmiles":"CCCC(=O)N[C@H]1/C(=N/OC(=O)Nc2ccccc2)O[C@H](CO)[C@@H](O)[C@@H]1O","inchiKey":"ITVRELFVFCOUMV-ZVZWZHPPSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL255476","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB07432"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL257975","canonicalSmiles":"O=P(O)(O)OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O","inchiKey":"NBSCHQHZLSJFNQ-VFUOTHLCSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"Glucose-6-Phosphate","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Glucose-6-Phosphate"],"crossReferences":{"drugbank":["DB04122"],"chEBI":["17719"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL259548","canonicalSmiles":"C[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@H]2CC[C@@]3(C)[C@@H](CC[C@]3(C)O)[C@@H]21","inchiKey":"IVFYLRMMHVYGJH-VLOLGRDOSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"BOLASTERONE","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["7.alpha.,17-dimethyltestosterone","Bolasterone","NSC-66233","U-19763"],"crossReferences":{"drugbank":["DB01471"],"chEBI":["34583"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL266481","canonicalSmiles":"CSCC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)Cc1c[nH]cn1)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)O)[C@@H](C)O","inchiKey":"MASNOZXLGMXCHN-ZLPAWPGGSA-N","drugType":"Protein","blackBoxWarning":false,"name":"GLUCAGON","yearOfFirstApproval":1998,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Baqsimi","Glucagen Hypokit","Glucagon","Glucagon Emergency Kit","Gvoke hypopen","Gvoke pfs"],"synonyms":["Glucagon","Glucagon recombinant"],"crossReferences":{"DailyMed":["glucagon"],"PubChem":["50112436"],"Wikipedia":["Glucagon"],"chEBI":["5391"]},"linkedTargets":{"rows":["ENSG00000215644"],"count":1},"linkedDiseases":{"rows":["EFO_0000545","MONDO_0005147","Orphanet_657","HP_0001943","MONDO_0005148","EFO_0000400","EFO_0001073","EFO_0007214","EFO_0007318"],"count":9},"description":"Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1998 and is indicated for diabetes mellitus and hypoglycemia and has 6 investigational indications."}
{"id":"CHEMBL270686","canonicalSmiles":"COc1ccnc2[nH]cc(-c3ccnc(N)n3)c12","inchiKey":"GGEWEQJWGGJUHO-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"MERIOLIN 3","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB08178"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL279516","canonicalSmiles":"O=C(NC1CCN(CCc2c[nH]c3ccccc23)CC1)c1ccccc1","inchiKey":"JXZZEXZZKAWDSP-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"INDORAMIN","maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Baratol","Doralese tiltab"],"synonyms":["Indoramin","WY 21901","WY-21901"],"crossReferences":{"PubChem":["29217568","49671666"],"Wikipedia":["Indoramin"],"drugbank":["DB08950"]},"childChemblIds":["CHEMBL2104941"],"description":"Small molecule drug with a maximum clinical trial phase of IV and is indicated for hypertension."}
{"id":"CHEMBL3039502","canonicalSmiles":"C[C@H](Nc1ncnc2nc[nH]c12)c1cc2cccc(Cl)c2c(=O)n1-c1ccccc1","inchiKey":"SJVQHLPISAIATJ-ZDUSSCGKSA-N","drugType":"Small molecule","blackBoxWarning":true,"name":"DUVELISIB","yearOfFirstApproval":2018,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Copiktra"],"synonyms":["Duvelisib","Duvelisib hydrate","Duvelisib monohydrate","INK-1147","INK-1197","IPI-145"],"crossReferences":{"DailyMed":["duvelisib"],"drugbank":["DB11952"]},"linkedTargets":{"rows":["ENSG00000171608","ENSG00000105851"],"count":2},"linkedDiseases":{"rows":["EFO_0000616","EFO_0000685","EFO_0000220","EFO_0000756","EFO_0000403","EFO_0005952","MONDO_0044881","EFO_0000311","EFO_0000565","EFO_0000211","MONDO_0100096","EFO_0000096","EFO_0000095","EFO_0001421","EFO_0000574","MONDO_0004979","EFO_1001051","MONDO_0018906","EFO_1000785","MONDO_0002083","EFO_0000181"],"count":21},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2018 and has 6 approved and 13 investigational indications. This drug has a black box warning from the FDA."}
{"id":"CHEMBL3039526","canonicalSmiles":"CN1CCC(C(=O)c2cccc(NC(=O)c3c(F)cc(F)cc3F)n2)CC1.CN1CCC(C(=O)c2cccc(NC(=O)c3c(F)cc(F)cc3F)n2)CC1.O=C(O)CCC(=O)O","inchiKey":"MSOIHUHNGPOCTH-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"LASMIDITAN SUCCINATE","yearOfFirstApproval":2020,"maximumClinicalTrialPhase":4,"parentId":"CHEMBL3039520","hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Reyvow"],"synonyms":["LY-573144","LY-683974","LY683974","Lasmiditan hemisuccinate","Lasmiditan succinate"],"crossReferences":{"DailyMed":["lasmiditan%20succinate"]},"linkedTargets":{"rows":["ENSG00000179097"],"count":1},"linkedDiseases":{"rows":["MONDO_0005277"],"count":1},"description":"Small molecule drug with a maximum clinical trial phase of IV that was first approved in 2020 and is indicated for migraine disorder."}
{"id":"CHEMBL3137323","canonicalSmiles":"Cl.O=C(N[C@H]1CN2CCC1CC2)c1cc2cccc(Cl)c2s1","inchiKey":"OIJYTJGIDVTCFF-ZOWNYOTGSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"ENCENICLINE HYDROCHLORIDE","maximumClinicalTrialPhase":3,"parentId":"CHEMBL2151572","hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["EVP-6124","EVP-6124 HYDROCHLORIDE","Encenicline hydrochloride"],"description":"Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications."}
{"id":"CHEMBL3137350","drugType":"Antibody","blackBoxWarning":false,"name":"DIRIDAVUMAB","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["CR-6261","CR6261","Diridavumab"],"description":"Antibody drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."}
{"id":"CHEMBL3185463","canonicalSmiles":"CN1CCN(c2ccccc2/C=C2\\SCCN(c3ccc(Cl)c(Cl)c3)C2=O)CC1","inchiKey":"LHYMPSWMHXUWSK-STZFKDTASA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"ELZASONAN","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Elzasonan"],"crossReferences":{"PubChem":["144210759"]},"childChemblIds":["CHEMBL3989903","CHEMBL3989805"],"linkedTargets":{"rows":["ENSG00000135312","ENSG00000179546"],"count":2},"linkedDiseases":{"rows":["MONDO_0002009"],"count":1},"description":"Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."}
{"id":"CHEMBL3286580","canonicalSmiles":"Fc1ccc2c(CCNCc3cccc(OCC(F)(F)C(F)F)c3)c[nH]c2c1","inchiKey":"YBAWYTYNMZWMMJ-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"IDALOPIRDINE","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Idalopirdine","LU AE-58054","LU-AE-58054","LU-AE58054","LY-483518","LY483518","Lu AE58054","Lu-ae58054","SGS-518","SGS518"],"crossReferences":{"drugbank":["DB11957"]},"linkedTargets":{"rows":["ENSG00000158748"],"count":1},"linkedDiseases":{"rows":["MONDO_0005090","MONDO_0004975"],"count":2},"description":"Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications."}
{"id":"CHEMBL3301581","drugType":"Protein","blackBoxWarning":true,"name":"ABALOPARATIDE","yearOfFirstApproval":2017,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Tymlos"],"synonyms":["Abaloparatide","BA-058","BA058","BIM-44058"],"crossReferences":{"DailyMed":["abaloparatide"]},"linkedTargets":{"rows":["ENSG00000160801"],"count":1},"linkedDiseases":{"rows":["EFO_0003931","EFO_0003854","EFO_0003882"],"count":3},"description":"Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2017 and is indicated for osteoporosis and has 2 investigational indications. This drug has a black box warning from the FDA."}
{"id":"CHEMBL3545070","drugType":"Enzyme","blackBoxWarning":false,"name":"VONAPANITASE","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["PRT-201","PRT201","Pancreatic elastase 1","Vonapanitase"],"linkedTargets":{"rows":["ENSG00000049540"],"count":1},"linkedDiseases":{"rows":["EFO_0003884","EFO_0004265"],"count":2},"description":"Enzyme drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications."}
{"id":"CHEMBL3545072","drugType":"Antibody","blackBoxWarning":false,"name":"LANDOGROZUMAB","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Anti-myostatin antibody","LY-2495655","LY2495655","Landogrozumab"],"linkedTargets":{"rows":["ENSG00000138379"],"count":1},"linkedDiseases":{"rows":["EFO_0002618","EFO_0002970","EFO_0000311"],"count":3},"description":"Antibody drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."}
{"id":"CHEMBL3545077","drugType":"Small molecule","blackBoxWarning":false,"name":"MK-1496","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Mk-1496"],"linkedTargets":{"rows":["ENSG00000166851"],"count":1},"linkedDiseases":{"rows":["EFO_0000616"],"count":1},"description":"Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL3545180","drugType":"Small molecule","blackBoxWarning":false,"name":"THELIATINIB","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["HMPL-309","Hmpl-309","Theliatinib","Xiliertinib"],"linkedTargets":{"rows":["ENSG00000146648"],"count":1},"linkedDiseases":{"rows":["EFO_0000311"],"count":1},"description":"Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL3545270","drugType":"Small molecule","blackBoxWarning":false,"name":"LY2969822","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Ly2969822"],"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL3590106","canonicalSmiles":"CC(C)Nc1cc(-c2c[nH]c(C(=O)N[C@H](CO)c3cccc(Cl)c3)c2)c(Cl)cn1","inchiKey":"KSERXGMCDHOLSS-LJQANCHMSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"ULIXERTINIB","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["BVD-ERK","Bvd-523","Ulixertinib","VRT-752271"],"crossReferences":{"drugbank":["DB13930"]},"linkedTargets":{"rows":["ENSG00000102882","ENSG00000100030"],"count":2},"linkedDiseases":{"rows":["EFO_0000198","EFO_0002618","EFO_0000616","EFO_1000218","EFO_1000616","EFO_0000222"],"count":6},"description":"Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications."}
{"id":"CHEMBL36506","canonicalSmiles":"CO[C@@H]1[C@@H](OC(N)=O)[C@@H](O)[C@H](Oc2ccc3c(O)c(NC(=O)c4ccc(O)c(CC=C(C)C)c4)c(=O)oc3c2C)OC1(C)C","inchiKey":"YJQPYGGHQPGBLI-KGSXXDOSSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"NOVOBIOCIN","yearOfFirstApproval":1964,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":true,"isApproved":true,"withdrawnNotice":{"countries":["United States"],"classes":["Dermatological toxicity"," Hematological toxicity"," Hepatotoxicity"],"year":2009},"tradeNames":["Albamycin t"],"synonyms":["Albamycin","Cathomycin","Novobiocin"],"crossReferences":{"PubChem":["26755282"],"Wikipedia":["Novobiocin"],"drugbank":["DB01051"],"chEBI":["28368"]},"childChemblIds":["CHEMBL3544972","CHEMBL3183453"],"description":"Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1964 and has 1 investigational indication. It was withdrawn in United States  in 2009 due to Dermatological toxicity,  Hematological toxicity and  Hepatotoxicity."}
{"id":"CHEMBL3707328","drugType":"Antibody","blackBoxWarning":false,"name":"GALCANEZUMAB","yearOfFirstApproval":2018,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Emgality"],"synonyms":["Galcanezumab","Galcanezumab-gnlm","LY-2951742","LY2951742"],"crossReferences":{"DailyMed":["galcanezumab-gnlm"]},"linkedTargets":{"rows":["ENSG00000110680","ENSG00000175868"],"count":2},"linkedDiseases":{"rows":["MONDO_0005277","EFO_1001219","EFO_0004616","EFO_0003843"],"count":4},"description":"Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2018 and is indicated for migraine disorder and has 2 investigational indications."}
{"id":"CHEMBL372764","canonicalSmiles":"CCCCCCCCCCCCCCCCCCOP(=O)([O-])OC1CC[N+](C)(C)CC1","inchiKey":"SZFPYBIJACMNJV-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"PERIFOSINE","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["KRX-0401","NSC-639966","Perifosine"],"crossReferences":{"PubChem":["144206916","225144339","499931"],"Wikipedia":["Perifosine"],"drugbank":["DB06641"],"chEBI":["67272"]},"description":"Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 38 investigational indications."}
{"id":"CHEMBL3900409","canonicalSmiles":"Cn1c(=O)oc2ccc(-c3ccc(C[C@@H](C#N)NC(=O)[C@@H]4CNCCCO4)cc3)cc21","inchiKey":"AEXFXNFMSAAELR-RXVVDRJESA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"BRENSOCATIB","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["AZD 7986","AZD-7986","AZD7986","Azd-7986","Azd7986","Brensocatib","INS-1007","INS1007"],"crossReferences":{"drugbank":["DB15638"]},"linkedTargets":{"rows":["ENSG00000109861"],"count":1},"linkedDiseases":{"rows":["MONDO_0100096","Orphanet_586","HP_0002110"],"count":3},"description":"Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications."}
{"id":"CHEMBL3989559","canonicalSmiles":"COc1ccnc(C[S+]([O-])c2nc3cc(OC(F)F)ccc3[n-]2)c1OC.O.[Na+]","inchiKey":"CGJRLPRCWSHOFU-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"PANTOPRAZOLE SODIUM","yearOfFirstApproval":2000,"maximumClinicalTrialPhase":4,"parentId":"CHEMBL1502","hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Pantoprazole sodium","Protonix","Protonix iv"],"synonyms":["Controloc control","Pantoprazole (as sodium)","Pantoprazole sodium","Pantoprazole sodium hydrate","Pantoprazole sodium sesquihydrate","Pantozol control","Somac control"],"crossReferences":{"DailyMed":["pantoprazole%20sodium"]},"linkedTargets":{"rows":["ENSG00000105675"],"count":1},"linkedDiseases":{"rows":["EFO_0003948","EFO_0000616","Orphanet_79292","EFO_0007549","HP_0100633"],"count":5},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2000 and has 3 approved and 2 investigational indications."}
{"id":"CHEMBL3990022","drugType":"Antibody","blackBoxWarning":false,"name":"VONLEROLIZUMAB","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["MOXR-0916","MOXR0916","Pogalizumab","R0-7021608","R07021608","RO7021608","Vonlerolizumab"],"description":"Antibody drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."}
{"id":"CHEMBL4279047","canonicalSmiles":"C[C@@H](Nc1nc(N[C@H](C)C(F)(F)F)nc(-c2cccc(Cl)n2)n1)C(F)(F)F","inchiKey":"QCZAWDGAVJMPTA-RNFRBKRXSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"VORASIDENIB","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["AG-881","Ag-881","Vorasidenib"],"childChemblIds":["CHEMBL4594378"],"linkedTargets":{"rows":["ENSG00000138413","ENSG00000182054"],"count":2},"linkedDiseases":{"rows":["EFO_0000326"],"count":1},"description":"Small molecule drug with a maximum clinical trial phase of III and has 1 investigational indication."}
{"id":"CHEMBL4297459","canonicalSmiles":"O=C1CCC(N2C(=O)c3cccc(CNC(=O)C4CC4)c3C2=O)C(=O)N1","inchiKey":"ZBXHNCURDISBRO-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CC-11006","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["CC 11006","CC-11006","Cc-11006"],"description":"Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL4297605","canonicalSmiles":"O=C(CN1CCC(CN2Cc3ccccc3C2=O)CC1)c1ccc(F)cc1","inchiKey":"RNRYULFRLCBRQS-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"ROLUPERIDONE","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["FMI","MIN-101 FREE BASE","Roluperidone"],"crossReferences":{"drugbank":["DB13080"]},"childChemblIds":["CHEMBL4298043"],"description":"Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications."}
{"id":"CHEMBL4297689","drugType":"Unknown","blackBoxWarning":false,"name":"ALT-801","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Alt-801"],"description":"Unknown drug with a maximum clinical trial phase of I (across all indications) and has 6 investigational indications."}
{"id":"CHEMBL4297721","drugType":"Unknown","blackBoxWarning":false,"name":"CDX-1140","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["CDX-1140","Cdx-1140"],"linkedTargets":{"rows":["ENSG00000101017"],"count":1},"linkedDiseases":{"rows":["EFO_0002618","EFO_0000616","EFO_0006859","MONDO_0015686","EFO_0000756","MONDO_0008170","EFO_0000681","EFO_0000403","MONDO_0007254","MONDO_0007576","EFO_1001469","EFO_0000305","EFO_0003060","EFO_0005221","EFO_1001951","MONDO_0001056","EFO_1000044","MONDO_0002158","EFO_0000182","EFO_0006544"],"count":20},"description":"Unknown drug with a maximum clinical trial phase of II (across all indications) and has 17 investigational indications."}
{"id":"CHEMBL4297754","drugType":"Oligonucleotide","blackBoxWarning":false,"name":"FITUSIRAN","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["ALN-57213","ALN-AT3SC","Aln-at3sc","Fitusiran"],"linkedTargets":{"rows":["ENSG00000117601"],"count":1},"linkedDiseases":{"rows":["Orphanet_448","Orphanet_98879","Orphanet_98878"],"count":3},"description":"Oligonucleotide drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications."}
{"id":"CHEMBL4297770","drugType":"Oligonucleotide","blackBoxWarning":false,"name":"INOTERSEN","maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":[],"synonyms":["GSK-2998728","ISIS 420915","ISIS-420915","Inotersen"],"linkedTargets":{"rows":["ENSG00000118271"],"count":1},"linkedDiseases":{"rows":["EFO_1001875","Orphanet_85447"],"count":2},"description":"Oligonucleotide drug with a maximum clinical trial phase of IV (across all indications) and has 2 investigational indications."}
{"id":"CHEMBL4297777","drugType":"Unknown","blackBoxWarning":false,"name":"LMB-100","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Anti-msln-pe24 cfp lmb-100","LMB-100","Lmb 100","Lmb-100","RG-7787","RG7787","RO-6927005","RO6927005","Ro6927005"],"linkedTargets":{"rows":["ENSG00000167658","ENSG00000102854"],"count":2},"linkedDiseases":{"rows":["EFO_0000588","EFO_0003860","EFO_0000571","EFO_0000311"],"count":4},"description":"Unknown drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications."}
{"id":"CHEMBL4297903","drugType":"Protein","blackBoxWarning":false,"name":"PEPTIDE B27PD","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Alnedlsswtaadt","Amino acids 125-138 of hla-b","B-27PD","B27PD","B27pd","Optiquel","Peptide b27pd"],"description":"Protein drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL4297939","drugType":"Unknown","blackBoxWarning":false,"name":"DS-1062","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["ADC DS-1062A","DATO-DXD","DS-1062","DS-1062A","DS1062","Datopotamab deruxtecan","Ds-1062","Ds-1062a"],"linkedTargets":{"rows":["ENSG00000198900","ENSG00000184292"],"count":2},"linkedDiseases":{"rows":["EFO_0003869","MONDO_0008903","MONDO_0007254","EFO_0003060"],"count":4},"description":"Unknown drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications."}
{"id":"CHEMBL4298023","drugType":"Unknown","blackBoxWarning":false,"name":"M-1095","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["ALX-0761","ALX0761","M-1095","M1095","Sonelokimab"],"linkedTargets":{"rows":["ENSG00000112116","ENSG00000112115"],"count":2},"linkedDiseases":{"rows":["EFO_0000676"],"count":1},"description":"Unknown drug with a maximum clinical trial phase of II and has 1 investigational indication."}
{"id":"CHEMBL4298100","drugType":"Unknown","blackBoxWarning":false,"name":"SAR-441236","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["SAR-441236","SAR441236","Sar 441236","Sar-441236","Sar441236"],"description":"Unknown drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL4298178","drugType":"Antibody","blackBoxWarning":false,"name":"TRASTUZUMAB DUOCARMAZINE","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["SYD-985","SYD985","Trastuzumab duocarmazine"],"linkedTargets":{"rows":["ENSG00000141736"],"count":1},"linkedDiseases":{"rows":["EFO_0000616","MONDO_0001056","EFO_0001075","EFO_0003968","EFO_0005537","EFO_0000478","MONDO_0011962","MONDO_0007254","EFO_0004243","MONDO_0024880","MONDO_0021251","MONDO_0001187"],"count":12},"description":"Antibody drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications."}
{"id":"CHEMBL4298209","drugType":"Antibody","blackBoxWarning":true,"name":"BELANTAMAB MAFODOTIN","yearOfFirstApproval":2020,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Blenrep"],"synonyms":["Belantamab mafodotin","Belantamab mafodotin-blmf","GSK-2857916","GSK2857916"],"crossReferences":{"DailyMed":["belantamab%20mafodotin-blmf"]},"linkedTargets":{"rows":["ENSG00000261456","ENSG00000188229","ENSG00000104833","ENSG00000137267","ENSG00000258947","ENSG00000101162","ENSG00000048462","ENSG00000137285","ENSG00000196230","ENSG00000176014"],"count":10},"linkedDiseases":{"rows":["EFO_0000616","EFO_0000403","EFO_0001378","Orphanet_85443"],"count":4},"description":"Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2020 and is indicated for multiple myeloma and neoplasm and has 2 investigational indications. This drug has a black box warning from the FDA."}
{"id":"CHEMBL4300153","drugType":"Small molecule","blackBoxWarning":false,"name":"PSMA-HBED-CC","yearOfFirstApproval":2020,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":[],"synonyms":[],"childChemblIds":["CHEMBL4297335"],"description":"Small molecule drug with a maximum clinical trial phase of IV that was first approved in 2020 and has 1 investigational indication."}
{"id":"CHEMBL4303470","canonicalSmiles":"CC(C)Oc1ccc(C(=O)N[C@H](CNC(=O)CN(C)C)Cc2ccc(-c3cn4cccc([C@H](C)O)c4n3)cc2)cc1Cl","inchiKey":"WHMXDBPHBVLYRC-OFVILXPXSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"GSK-923295A","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["GSK-295","GSK-923295","GSK-923295A","GSK923295","Gsk-923295a","Gsk923295"],"description":"Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL444963","canonicalSmiles":"CCC(=O)O[C@H]1[C@H](C)O[C@@H](O[C@@H]2[C@@H](C)O[C@@H](O[C@@H]3[C@@H](OC)[C@H](OC(=O)CC)CC(=O)O[C@H](C)C/C=C/C=C/[C@H](O)[C@H](C)C[C@@H]3CC=O)[C@H](O)[C@H]2N(C)C)C[C@@]1(C)O","inchiKey":"DMUAPQTXSSNEDD-QALJCMCCSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL444963","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"PubChem":["144204186"],"drugbank":["DB13456"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL459265","canonicalSmiles":"CN(C)c1ccc(C(=C2C=CC(=[N+](C)C)C=C2)c2ccc(N(C)C)cc2)cc1","inchiKey":"LGLFFNDHMLKUMI-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"HEXAMETHYL PARAROSANILINE","yearOfFirstApproval":1982,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":[],"synonyms":[],"crossReferences":{"PubChem":["124890459"],"drugbank":["DB00406"],"chEBI":["77181"]},"childChemblIds":["CHEMBL64894"],"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1982 and has 3 investigational indications."}
{"id":"CHEMBL4594292","canonicalSmiles":"CN1CCC(COc2cnc(-c3cccc(Cn4nc(-c5cccc(C#N)c5)ccc4=O)c3)nc2)CC1.Cl.O","inchiKey":"KZVOMLRKFJUTLK-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"TEPOTINIB HYDROCHLORIDE","yearOfFirstApproval":2021,"maximumClinicalTrialPhase":4,"parentId":"CHEMBL3402762","hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Tepmetko"],"synonyms":["MSC2156119J","Msc2156119j","Tepotinib hydrochloride"],"linkedTargets":{"rows":["ENSG00000105976"],"count":1},"linkedDiseases":{"rows":["EFO_0000616","EFO_0003060"],"count":2},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2021 and is indicated for non-small cell lung carcinoma and has 1 investigational indication."}
{"id":"CHEMBL461332","canonicalSmiles":"CC1(C)O[C@@H]2C[C@H]3[C@@H]4C[C@H](F)C5=CC(=O)C=C[C@]5(C)[C@@]4(Cl)[C@@H](Cl)C[C@]3(C)[C@]2(C(=O)CO)O1","inchiKey":"NJNWEGFJCGYWQT-VSXGLTOVSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"FLUCLORONIDE","maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Topilar"],"synonyms":["Fluclorolone acetonide","Flucloronide","RS-2252"],"crossReferences":{"drugbank":["DB08973"]},"description":"Small molecule drug with a maximum clinical trial phase of IV."}
{"id":"CHEMBL461343","canonicalSmiles":"N/C(=N\\O)N/N=C/c1c(Cl)cccc1Cl","inchiKey":"QKIQJNNDIWGVEH-UUILKARUSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"GUANOXABENZ","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["43-663","Guanoxabenz"],"crossReferences":{"Wikipedia":["Guanoxabenz"],"drugbank":["DB13410"]},"description":"Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL4650489","drugType":"Unknown","blackBoxWarning":false,"name":"MAK-683","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["MAK-683","MAK683","Mak 683","Mak-683","Mak683"],"description":"Unknown drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL469099","canonicalSmiles":"CC1(C)CC(=O)c2sc(N3CCOCC3)nc2C1","inchiKey":"DZXMARZBAUMWLK-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL469099","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB07073"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL4802129","canonicalSmiles":"C[C@@H]1NC(=O)[C@H](Cc2c[nH]cn2)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@@H]2CCCN2C(=O)[C@H]2CCCN2C(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@@H]2CSSC[C@H](NC1=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N1CCC[C@@H]1C(=O)N[C@@H](CCN)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N2","inchiKey":"MKXOUIKTXREBLX-NDKBASPVSA-N","drugType":"Protein","blackBoxWarning":false,"name":"BALIXAFORTIDE","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Balixafortide","POL-6326","POL6326","Pol6326"],"linkedTargets":{"rows":["ENSG00000121966"],"count":1},"linkedDiseases":{"rows":["EFO_0000198","EFO_0000339","EFO_0000095","MONDO_0007254","EFO_0000222","EFO_0001378","EFO_0000612","MONDO_0003541"],"count":8},"description":"Protein drug with a maximum clinical trial phase of III (across all indications) and has 7 investigational indications."}
{"id":"CHEMBL4802161","canonicalSmiles":"CC(=O)c1c(C)c2cnc(Nc3ccc(C4CCNCC4)cn3)nc2n(C2CCCC2)c1=O","inchiKey":"SGJLSPUSUBJWHO-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"DALPICICLIB","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Dalpiciclib","Shr-6390"],"description":"Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."}
{"id":"CHEMBL48582","canonicalSmiles":"CS(=O)(=O)O.C[C@H](NCc1ccc(OCc2cccc(F)c2)cc1)C(N)=O","inchiKey":"YKOCHIUQOBQIAC-YDALLXLXSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"SAFINAMIDE MESYLATE","yearOfFirstApproval":2017,"maximumClinicalTrialPhase":4,"parentId":"CHEMBL396778","hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Xadago"],"synonyms":["EMD 1195686","NW 1015","NW-1015","PNU 151774E","PNU-151774E","Safinamide mesilate","Safinamide mesylate","Safinamide methanesulfonate","Safinamide methansulfonate"],"crossReferences":{"DailyMed":["safinamide%20mesylate"]},"linkedTargets":{"rows":["ENSG00000069535"],"count":1},"linkedDiseases":{"rows":["MONDO_0005180"],"count":1},"description":"Small molecule drug with a maximum clinical trial phase of IV that was first approved in 2017 and is indicated for parkinson disease."}
{"id":"CHEMBL488436","canonicalSmiles":"Cc1ncc(-c2ccnc(Nc3ccc(S(C)(=O)=O)cc3)n2)n1C(C)C","inchiKey":"WJRRGYBTGDJBFX-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"AZD-5438","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["AZD-5438","Azd 5438","Azd-5438"],"childChemblIds":["CHEMBL454649"],"linkedTargets":{"rows":["ENSG00000250506","ENSG00000156345","ENSG00000164885","ENSG00000134058","ENSG00000123374","ENSG00000135446","ENSG00000155111","ENSG00000105810","ENSG00000167258","ENSG00000059758","ENSG00000136807","ENSG00000138395","ENSG00000058091","ENSG00000248333","ENSG00000117266","ENSG00000132964","ENSG00000065883","ENSG00000102225","ENSG00000170312","ENSG00000185324"],"count":20},"linkedDiseases":{"rows":["EFO_0000616"],"count":1},"description":"Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL497058","canonicalSmiles":"Cc1ccc(NC(=O)NCCSCc2ccc(CN(C)C)o2)cc1Cl","inchiKey":"WEYNBWVKOYCCQT-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL497058","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB08027"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL501822","canonicalSmiles":"O=C(O)Cc1ccc(O)c([N+](=O)[O-])c1","inchiKey":"QBHBHOSRLDPIHG-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL501822","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB08294"],"chEBI":["546274"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL521589","canonicalSmiles":"CN(C)C(=O)Oc1cc(OC(=O)N(C)C)cc(C(O)CNC(C)(C)C)c1","inchiKey":"ANZXOIAKUNOVQU-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"BAMBUTEROL","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Bambuterol"],"crossReferences":{"PubChem":["56463628"],"Wikipedia":["Bambuterol"],"drugbank":["DB01408"],"chEBI":["553827"]},"childChemblIds":["CHEMBL1603534"],"linkedTargets":{"rows":["ENSG00000169252"],"count":1},"linkedDiseases":{"rows":["HP_0006536","EFO_0001361","EFO_0009661","MONDO_0004979","EFO_0000341"],"count":5},"description":"Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications."}
{"id":"CHEMBL526330","canonicalSmiles":"O[C@H]1[C@H]2CC[C@](O)(N2)[C@@H](O)[C@@H]1O","inchiKey":"FXFBVZOJVHCEDO-IBISWUOJSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CALYSTEGINE B2","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB04658"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL542103","canonicalSmiles":"CC(C)c1cccc(C(C)C)c1NC(=O)NCC1(c2ccc(N(C)C)cc2)CCCC1.Cl","inchiKey":"SDOOGTHIDFZUNM-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"NEVANIMIBE HYDROCHLORIDE","maximumClinicalTrialPhase":2,"parentId":"CHEMBL46423","hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["ATR-101","ATR-101 HYDROCHLORIDE","Atr-101","Nevanimibe hydrochloride","PD 132301-02","PD-132301 HYDROCHLORIDE","PD-132301-02","PD-132301-2","PD132301-02","PD132301-2"],"description":"Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."}
{"id":"CHEMBL545","canonicalSmiles":"CCO","inchiKey":"LFQSCWFLJHTTHZ-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"ALCOHOL","maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Ablysinol","Ethanol","Ethyl Alcohol","Methylated mineral","Spirigel","Surg"],"synonyms":["Alcohol","Alcohol 190 proof","Alcohol 95%","Alcohol anhydrous","Alcohol denat.","Alcohol denatured","Alcohol determination--alcohol","Alcohol, Diluted","Alcohol, Rubbing","Alcohol, absolute","Alcohol, dehydrated","Alcohol, denatured","Alcohol, diluted","Alcohol, rubbing","Alcohol,dehydrated","Alcohol,denatured","Alcohol,ethyl","Alcohol,sda","Alcoholum","Anhydrous ethanol","B3324","Dehydrated alcohol","Dehydrated ethanol","E1510","Edible alcohol","Ethanol","Ethanol in alcoholic beverages","Ethanol, anhydrous","Ethanol, dehydrated","Ethanolum","Ethyl alcohol","Ethyl alcohol, absolute","Ethyl alcohol, dehydrated","Ethylicum","FEMA NO. 2419","Grain alcohol","NCI-C03134","NSC-85228","PM-6193-200","Sd alcohol","Tecsol","Vodka"],"crossReferences":{"PubChem":["144209708","17389892"],"TG-GATEs":["137"],"Wikipedia":["Ethanol"],"drugbank":["DB00898"],"chEBI":["16236"]},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) and has 3 approved and 36 investigational indications."}
{"id":"CHEMBL560","canonicalSmiles":"CC(C)=CCN1CC[C@@]2(C)c3cc(O)ccc3C[C@@H]1[C@@H]2C","inchiKey":"VOKSWYLNZZRQPF-GDIGMMSISA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"PENTAZOCINE","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Pentazocine"],"crossReferences":{"Wikipedia":["Pentazocine"],"drugbank":["DB00652"],"chEBI":["7982"]},"childChemblIds":["CHEMBL1200327","CHEMBL2360021"],"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL572964","canonicalSmiles":"O=S(=O)(O)O","inchiKey":"QAOWNCQODCNURD-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"SULFURIC ACID","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Anhydrous sulfuric acid","Brimstone acid","E-513","E513","INS NO.513","INS-513","NSC-248648","NSC-38965","Sulfuric acid","Sulphuricum acidum","Tetraoxosulfuric acid"],"crossReferences":{"PubChem":["144207681"],"Wikipedia":["Sulfuric_acid"],"drugbank":["DB11309"],"chEBI":["26836"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL573","canonicalSmiles":"O=C(O)c1cccnc1","inchiKey":"PVNIIMVLHYAWGP-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"NIACIN","maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Niacin","Niacin Td","Niacor","Niaspan","Niaspan Er","Niaspan titration starter pack","Nicangin","Nicolar","Simcor","Wampocap"],"synonyms":["Acidum nicotinicum","NSC-169454","Niacin","Niacin extended release","Nicotinate","Nicotinic acid","Vitamin b3"],"crossReferences":{"DailyMed":["niacin"],"PubChem":["104171277","11112153","144203888","144208618","144213221","170465044","174007257","8139875"],"TG-GATEs":["81"],"Wikipedia":["Niacin"],"drugbank":["DB00627"],"chEBI":["15940"]},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) and has 10 approved and 30 investigational indications."}
{"id":"CHEMBL590284","canonicalSmiles":"COc1ccc2c(c1)c(CC(=O)O)c(C)n2C(=O)c1ccc(I)cc1","inchiKey":"CXBFZYKAVCAPSV-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"IODOINDOMETHACIN","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Iodoindomethacin"],"crossReferences":{"drugbank":["DB07983"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL66526","canonicalSmiles":"Cc1ccc(Cn2cnc(-c3cccs3)c2)cc1","inchiKey":"UMOFOLLUKPBVQG-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL66526","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB03030"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL730","canonicalSmiles":"O=[N+]([O-])OCC(CO[N+](=O)[O-])O[N+](=O)[O-]","inchiKey":"SNIOPGDIGTZGOP-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":true,"name":"NITROGLYCERIN","yearOfFirstApproval":1981,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Coro-nitro","Deponit 10","Deponit 5","Glytrin","Gonitro","Lenitral 7.5","Minitran","Minitran 10","Minitran 15","Minitran 5","Natirose","Nitriderm tts","Nitro iv","Nitro-bid","Nitro-dur","Nitro-mack ret","Nitrocine","Nitrocontin continus","Nitroglycerin","Nitrol","Nitrolingual","Nitrolingual pumpspray","Nitromin","Nitromist","Nitronal","Nitrostat","Percutol","Rectiv","Rectogesic","Suscard buccal","Sustac","Transderm-nitro","Transiderm-nitro 10","Transiderm-nitro 5","Tridil","Trintek 10","Trintek 15","Trintek 5"],"synonyms":["C01DA02","Chlormethine oxide hydrochloride","Diluted nitroglycerin","Glonoinum","Glyceryl Trinitrate","Glyceryl trinitrate","Glyceryl trinitrate solution","Imx-150","Mechlorethamine oxide hcl","Mitomen","Mustron","Nitora","Nitroglycerin","Nitroglycerin tablets","Nitromin hydrochloride","Transderm-Nitro","Trinitrin","Trinitrin tablets","Trinitrine"],"crossReferences":{"DailyMed":["nitroglycerin"],"Wikipedia":["Nitroglycerin"],"drugbank":["DB00727"],"chEBI":["28787"]},"linkedTargets":{"rows":["ENSG00000061918","ENSG00000123201"],"count":2},"linkedDiseases":{"rows":["EFO_0003086","EFO_0004234","EFO_0009846","EFO_1000657","EFO_0000373","HP_0031217","EFO_0003882","EFO_1001145","EFO_1000994","EFO_1001951","EFO_0003913","HP_0012390","EFO_1000783","HP_0000938","EFO_1001375","EFO_0000544","EFO_0003144","EFO_0000712","MONDO_0008903","EFO_1001993","EFO_0009552","EFO_0003917","EFO_0000685","MONDO_0005149","EFO_0002687","EFO_1001395","EFO_0001645","EFO_0000319","EFO_0003843","EFO_0003060","EFO_0000537","HP_0100806","EFO_0000546","MP_0001845","EFO_0008583","EFO_0000612","HP_0031273","MONDO_0004857","EFO_0004265","EFO_0005251"],"count":40},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1981 and has 9 approved and 25 investigational indications. This drug has a black box warning from the FDA."}
{"id":"CHEMBL772","canonicalSmiles":"COC(=O)[C@H]1[C@H]2C[C@@H]3c4[nH]c5cc(OC)ccc5c4CCN3C[C@H]2C[C@@H](OC(=O)c2cc(OC)c(OC)c(OC)c2)[C@@H]1OC","inchiKey":"QEVHRUUCFGRFIF-MDEJGZGSSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"RESERPINE","yearOfFirstApproval":1960,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":true,"isApproved":true,"withdrawnNotice":{"countries":["United States"]},"tradeNames":["Hiserpia","Rau-sed","Reserpine","Sandril","Serpalan","Serpanray","Serpasil","Serpate","Serpivite"],"synonyms":["Apoplon","ENT-50146","NSC-237659","NSC-59272","Reserpine","Reserpinum"],"crossReferences":{"PubChem":["107574","144204658","144209593","144210855","170465405","17389743","26752948","50105550","50105551","50105552","50105553","56463068","90341213"],"Wikipedia":["Reserpine"],"drugbank":["DB00206"],"chEBI":["28487"]},"linkedTargets":{"rows":["ENSG00000165646"],"count":1},"linkedDiseases":{"rows":["EFO_0003914","EFO_0003777","EFO_0002610","EFO_0001361","HP_0003124","EFO_0001645","EFO_0003763","EFO_0004701","MONDO_0005148","EFO_0000400","EFO_0000537"],"count":11},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1960 and is indicated for hypertension and has 9 investigational indications. It was withdrawn in United States."}
{"id":"CHEMBL897","canonicalSmiles":"CCCN(CCC)S(=O)(=O)c1ccc(C(=O)O)cc1","inchiKey":"DBABZHXKTCFAPX-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"PROBENECID","yearOfFirstApproval":1951,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Benemid","Benuryl","Probalan","Probampicin","Probecid","Probenecid"],"synonyms":["HC 5006","NSC-18786","Probenate","Probenecid","Probenecidum"],"crossReferences":{"DailyMed":["probenecid"],"PubChem":["11112135","144203879","144209308","144213245","170464839","17389752","26747055","26747056","26751571","50100375","56424104","855953"],"Wikipedia":["Probenecid"],"drugbank":["DB01032"],"chEBI":["8426"]},"linkedTargets":{"rows":["ENSG00000197901","ENSG00000168065","ENSG00000149452"],"count":3},"linkedDiseases":{"rows":["EFO_0000616","EFO_0003035","EFO_0004274","EFO_0005222","EFO_0001073","EFO_0003103","EFO_0000474","EFO_0000544","EFO_0003144","MONDO_0001314","EFO_0007328","EFO_1001207","MONDO_0043510","MONDO_0007079","EFO_0000400","MONDO_0005148"],"count":16},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1951 and is indicated for gout and has 12 investigational indications."}
{"id":"CHEMBL91238","canonicalSmiles":"CC(C)NNC(=O)COc1ccc(Cl)cc1","inchiKey":"GGECDTUJZOXAAR-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"IPROCLOZIDE","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Iproclozide","PC-603"],"crossReferences":{"Wikipedia":["Iproclozide"],"drugbank":["DB09247"]},"description":"Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL995","canonicalSmiles":"CCCCc1nc(Cl)c(CO)n1Cc1ccc(-c2ccccc2-c2nn[n-]n2)cc1.[K+]","inchiKey":"OXCMYAYHXIHQOA-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":true,"name":"LOSARTAN POTASSIUM","yearOfFirstApproval":1995,"maximumClinicalTrialPhase":4,"parentId":"CHEMBL191","hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Cozaar","Losaprex","Losartan potassium"],"synonyms":["Aradois","Cozaar","DU PONT-753","DUP 753","DUP-753","E-3340","Hyzaar","L-158086","Losacar","Losartan monopotassium salt","Losartan potassium","Losata","MK-0954","MK0954","Nu-lotan","Presartan-50","Tancin","Zaart"],"crossReferences":{"DailyMed":["losartan%20potassium"],"PubChem":["49665951","49681581"]},"linkedTargets":{"rows":["ENSG00000144891"],"count":1},"linkedDiseases":{"rows":["EFO_0002618","EFO_0003086","EFO_0000275","EFO_0003095","HP_0000093","MONDO_0002462","Orphanet_558","EFO_0000537","EFO_0004232","EFO_0003896","MONDO_0001134","EFO_0002517","EFO_0000712","EFO_0003884","MONDO_0005148","EFO_0000668"],"count":16},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1995 and has 5 approved and 8 investigational indications. This drug has a black box warning from the FDA."}
